Online Registration is Open!
Register by Friday, December 11 to Save $600 off standard rates.
Printed from the IBC Life Sciences Web site on November 28, 2015 3:09 PM ET.
Page location: http://www.ibclifesciences.com/TIDES/overview.xml
May 09-12, 2016
Long Beach Convention & Entertainment Center
Long Beach, CA
IBC's 18th Annual TIDES 2016 conference and exhibition is the #1 industry forum for CMC, clinical and discovery scientists to share strategies to accelerate oligonucleotide and peptide product development. TIDES 2016 is the only event in the field to provide complete coverage of the oligonucleotide and peptide market from discovery to manufacturing. By attending, you will learn from multiple case studies designed to facilitate scientific exchange and networking to improve your oligo and peptide drug development and manufacturing operations. Returning to California with an expanded program in 2016 we hope you can join the IBC Team and over 800 expected attendees from around the world!
Give Your Input on Topics/Speakers for the 2016 Program
Contact the TIDES Conference Producer Today: Michael Keenan at Mkeenan@ibcusa.com or Tel: 949-276-2634.
Mixed-Incretin Receptor Biochemical Signaling at Multiple Receptors
Richard DiMarchi (Speaker Bio)
Standiford H. Cox Professor of Chemistry and Linda & Jack Gill Chair in Biomolecular Sciences
Drisapersen: Case Study
Robert Baffi, Ph.D.
Executive VP, Technical Operations
Quark's Long History of Oligonucleotide Development
Danny Zurr, Ph.D.
Chairman and Chief Executive Officer
Quark Pharmaceuticals Inc.
"The premier event to obtain an overview on hot topics in oligos and peptides and to network with opinion leaders" - Alex Fässler, Bachem AG, Switzerland
"TIDES always manages to be interesting for industry and academia alike" - Roland Brock, Radboud University Medical Centre
"We started attending TIDES five years ago on the recommendation of an oligo therapeutics client. We find that this venue offers unique access to 'C' level scientists from around the globe and the lectures are… first-rate" - Tom Falzareno, Tandem Labs